Tillman U. Gerngross (left) has joined SV Life Sciences as a venture partner as of October 2006. In this capacity he will review investment opportunities in the therapeutic protein and antibody space as well as explore new startup opportunities. Dr. Gerngross was a cofounder of GlycoFi and served as the company's CSO until its acquisition by Merck & Co. in June 2006. He will continue serving as chairman of GlycoFi's scientific advisory board and as an advisor to Merck's worldwide licensing and external research organization. In addition, Dr. Gerngross holds faculty positions at Dartmouth College's Thayer School of Engineering and departments of biology and chemistry.

James McArdle has been named vice president of chemistry, manufacturing and controls at Archemix (Cambridge, MA, USA). Dr. McArdle has more than 20 years of pharmaceutical development experience, most recently as vice president of the quality assurance department at Isis Pharmaceuticals.

Quantum Genomics (Jersey City, NJ, USA) has announced the appointment of Fabrice Balavoine as head of research. Dr. Balavoine was most recently head of drug development at Cerep, and previously served as project leader at the Ecole Nationale Supérieure de Chimie in Paris and at Harvard Medical School.

Pablo J. Cagnoni has been promoted to vice president and chief medical officer of OSI Pharmaceuticals (Melville, NY, USA). He has almost 20 years of clinical development experience in oncology, previously serving as vice president, clinical development and medical affairs at OSI. Before joining the company in 2004, Dr. Cagnoni was vice president of clinical development at Allos Therapeutics.

BioAlliance Pharma (Paris) has named Nicolas Fellmann as CFO. Mr. Fellmann has more than 10 years experience in the pharmaceutical industry, previously serving as a director in the finance department of Pfizer France.

Ambit Biosciences (San Diego) has announced several management appointments: Kerry Kelly, former associate general counsel for The Scripps Research Institute, as vice president and general counsel; Edward Shin, who previously held business development positions at Affinium Pharmaceuticals and Xencor, as senior director of corporate development; Robert Armstrong, former senior director of research at Chiron Biopharma, as senior director of pharmacology; and Mark Holladay, previously senior director of medicinal chemistry at Discovery Partners International, as senior director of chemistry. Additionally, Ambit has promoted Daniel Treiber to the position of director of molecular biology and technology development.

Idexx Laboratories (Westbrook, ME, USA) has announced the appointment of Irene Kerr as corporate vice president for worldwide operations. She joins the company from MDS Inc., where she served as senior vice president,strategic initiatives and investments.

David M. Lawrence, retired chairman and CEO of Kaiser Foundation Health Plan and Kaiser Foundation Hospitals, has joined the board of directors of Dynavax Technologies (Berkeley, CA, USA). Dynavax also announced that Jan Leschly, chairman and partner at Care Capital, who had served on the board since 2002, has resigned.

Early-stage company Triton BioSystems (Chelmsford, MA, USA) has named Donald S. Masters president and CEO. Dr. Masters has over 27 years experience in biotech, holding chief executive positions at startups including C3 Scientific, Bion and Oxigene. Most recently, he served as CEO of Esperance Pharmaceuticals.

John C. Moran has been appointed to the board of directors of Anika Therapeutics (Woburn, MA, USA), succeeding Harvey Sadow, who has retired from the board. Mr. Moran served as president of Synthes Spine, a division of Synthes USA. Since leaving Synthes in 1997, he has been a private investor in a number of companies, mostly in the medical device field.

The board of directors of Advaxis (N. Brunswick, NJ, USA) has appointed Thomas A. Moore to serve as chairman and CEO. Mr. Moore is currently a board member of Alteon, and was president and CEO of Biopure from 2002 to 2004. He replaces Roni Appel, who will continue to serve on Advaxis's board, as CEO.

Endo Pharmaceuticals (Chadds Ford, PA, USA) has appointed Charles A. Rowland, Jr. as executive vice president, CFO and treasurer. Mr. Rowland has more than 20 years of pharma industry experience, most recently as senior vice president and CFO of Biovail Pharmaceuticals. In addition, Endo announced that David E. Kerr has been promoted from vice president, business development to senior vice president, commercial business.

Ilypsa (Santa Clara, CA, USA) has announced the election of Samuel R. Saks (left) to its board of directors. Dr. Saks is cofounder and CEO of Jazz Pharmaceuticals, and was previously company group chairman at ALZA Corp. and a member of the Johnson & Johnson pharmaceutical operating committee. In addition, Ilypsa announced the promotion of cofounder Gerrit Klaerner to the position of senior vice president and chief business officer.

Early-stage company Predictive Biosciences (Lexington, MA, USA), on the heels of securing $10 million in Series A financing, has named Tony Shuber, formerly executive vice president and chief technology officer for Exact Sciences, as its chief technology officer.

Peter Thornton and Timothy R. Wright have been named to the board of directors of Antigenics (New York). Mr. Thornton was formerly CFO of Antigenics and senior vice president of business operations at Elan, and is currently president and COO of Circ Pharma. Mr. Wright is currently chairman of ParagonRx and founder of Mortimer Capital. He was formerly president of global commercial operations at Elan.